Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2155-2158

  Sausville, E A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; CYTOTOXIC AGENT; DOXORUBICIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; DNA DAMAGE; GENE EXPRESSION REGULATION; MITOSIS INHIBITION; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZOQUINONES; BREAST NEOPLASMS; DRUG SYNERGISM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; RETINOBLASTOMA PROTEIN; RIFABUTIN; TUMOR CELLS, CULTURED;

EID: 0034886833     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (32)

1. Recombinant humanized anti-HER2antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing breast cancer xenografts
2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast carrcinoma that overexpresses HER2
3. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
4. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
5. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines
6. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhjanced by coadministration of ZD1839 (Iressa), and inhibitor of EGFR tyrosine kinase
7. Enhanced chemosensitivity to CPT-11 with proteosome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition
8. The chkl protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
9. The radiosensitizing agent 7-hydroxystaurosporine(UCN-01) inhibits the DNA damage checkpoint kinase hChkl
10. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
11. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
12. Modulation of Hsp 90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB and schedule dependent manner
13. Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus
14. Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185
15. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins
16. Herbimycin A induces the 20S proteosome and ubiquitin-dependent degradation of receptor tyrsosine kinases
17. Polyubiquitination and proteosomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin
18. Inhibiton of heat shock protein HSP90-pp6Ov-src heteroprotein complex formation by bexzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
19. Structure and in vivo function of Hsp 90
20. Destabilization of raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen activated protein kinase signalling pathway
21. Geldanamycin and its analog 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts
22. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent
23. Benzoquinoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition
24. Phase I pharmacological study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors
25. Phase I trial of the heat shock protein 90(HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17aag). Pharmacoklinetic (PK) profile and pharmacodynamic endpoints
26. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in patients (pts) with advanced solid malignancies
27. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
28. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt dependent pathway
29. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine needle aspiration: Implications for early prediction of breast cancer response to neoadjuvant treatment
30. Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: Evidence against the involvement of c-src or DT-diaphorase
31. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
32. Mechanisms of Taxol-induced cell death are concentration dependent